Cellular Goods PLC (LSE:CBX) has filed its first patent application related to the use of cannabinoids for skin brightening to overcome changes as people age and during periods of hormonal change such as pregnancy.
The lab-generated CBD product specialist, which boasts ex-footballer David Beckham as a backer, said existing products rely on active ingredients such as Vitamin C, exfoliating acids and hydroquinones, which, while effective, can cause skin irritation and sensitivity.
Results from in-vitro human tissue models carried out by Cellular Goods have suggested that lab-made cannabinoids, namely cannabigerol (CBG), can improve the effectiveness of certain active ingredients used in traditional skin brightening products.
“These findings provide the basis for a new class of skin brightening solutions that can improve skin tone evenness associated with various factors, such as melasma and hyperpigmentation.”
Cellular Goods has incorporated these findings into its patent application, 'Dermal Composition Comprising Cannabinoid and Derivatives Thereof', filed on 26 April 2022 with the UK Intellectual Property Office.
Products such as a Rejuvenating Cannabinoid Face Serum, the UK's first CBG-based serum to prevent the signs of ageing caused by UV light exposure and inflammation, are already being offered to some customers, it said.
Anna Chokina, chief executive, said: " From having skin brightening properties, through to helping prevent the signs of ageing caused by UV light exposure and inflammation, cannabinoids have a number of skincare benefits that we are only just starting to understand.
“The filing of this patent based on our own research is part of our efforts to help unveil the benefits of cannabinoids, as well as to develop science-backed innovations that can improve people's wellness. “